These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 33820697)
1. National trends in clinical and pathologic staging for upper tract urothelial carcinoma: Implications for neoadjuvant chemotherapy. Rodrigues Pessoa R; Morrison JC; Konety B; Gershman B; Maroni P; Kukreja JB; Cost N; Flaig T; Kessler E; Sharma P; Kim SP Urol Oncol; 2021 Dec; 39(12):832.e9-832.e15. PubMed ID: 33820697 [TBL] [Abstract][Full Text] [Related]
2. Pathologic stage as a surrogate for oncologic outcomes after receipt of neoadjuvant chemotherapy for high-grade upper tract urothelial carcinoma. Singla N; Christie A; Freifeld Y; Ghandour RA; Woldu SL; Clinton TN; Petros FG; Robyak H; Yeh HC; Fang D; Enikeev D; Bagrodia A; Sagalowsky AI; Lotan Y; Raman JD; Matin SF; Margulis V Urol Oncol; 2020 Dec; 38(12):933.e7-933.e12. PubMed ID: 32430254 [TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy. Leow JJ; Chong YL; Chang SL; Valderrama BP; Powles T; Bellmunt J Eur Urol; 2021 May; 79(5):635-654. PubMed ID: 32798146 [TBL] [Abstract][Full Text] [Related]
4. Does neoadjuvant chemotherapy have therapeutic benefit for node-positive upper tract urothelial carcinoma? Results of a multi-center cohort study. Shigeta K; Matsumoto K; Ogihara K; Murakami T; Anno T; Umeda K; Izawa M; Baba Y; Sanjo T; Shojo K; Tanaka N; Takeda T; Morita S; Kosaka T; Mizuno R; Arita Y; Akita H; Jinzaki M; Kikuchi E; Oya M Urol Oncol; 2022 Mar; 40(3):105.e19-105.e26. PubMed ID: 34454822 [TBL] [Abstract][Full Text] [Related]
5. Contemporary Trends of Systemic Neoadjuvant and Adjuvant Intravesical Chemotherapy in Patients With Upper Tract Urothelial Carcinomas Undergoing Minimally Invasive or Open Radical Nephroureterectomy: Analysis of US Claims on Perioperative Outcomes and Health Care Costs. Del Giudice F; van Uem S; Li S; Vilson FL; Sciarra A; Salciccia S; Busetto GM; Maggi M; Tiberia L; Viscuso P; Canale V; Panebianco V; Pecoraro M; Ferro M; Moschini M; Krajewski W; D'Andrea D; Cacciamani GE; Mari A; Soria F; Porpiglia F; Fiori C; Amparore D; Checcucci E; Autorino R; De Berardinis E; Chung BI Clin Genitourin Cancer; 2022 Apr; 20(2):198.e1-198.e9. PubMed ID: 35031226 [TBL] [Abstract][Full Text] [Related]
6. Impact of Neoadjuvant Chemotherapy on Pathologic Response in Patients With Upper Tract Urothelial Carcinoma Undergoing Extirpative Surgery. Almassi N; Gao T; Lee B; Stein RJ; Haber GP; Ornstein MC; Rini BI; Gilligan TD; Garcia JA; Stephenson AJ; Grivas P Clin Genitourin Cancer; 2018 Dec; 16(6):e1237-e1242. PubMed ID: 30217764 [TBL] [Abstract][Full Text] [Related]
7. Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review. Aziz A; Dobruch J; Hendricksen K; Kluth LA; Necchi A; Noon A; Rink M; Roghmann F; Seiler R; Gontero P; Kassouf W; Shariat SF; Xylinas E; World J Urol; 2017 Sep; 35(9):1401-1407. PubMed ID: 28074261 [TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant chemotherapy for upper tract urothelial carcinoma. Kim DK; Cho KS Transl Cancer Res; 2020 Oct; 9(10):6576-6582. PubMed ID: 35117267 [TBL] [Abstract][Full Text] [Related]
9. The clinicopathological characteristics of muscle-invasive bladder recurrence in upper tract urothelial carcinoma. Shigeta K; Matsumoto K; Ogihara K; Murakami T; Anno T; Umeda K; Izawa M; Baba Y; Sanjo T; Shojo K; Tanaka N; Takeda T; Kosaka T; Mizuno R; Mikami S; Kikuchi E; Oya M Cancer Sci; 2021 Mar; 112(3):1084-1094. PubMed ID: 33368857 [TBL] [Abstract][Full Text] [Related]
10. Predictive model for systemic recurrence following cisplatin-based neoadjuvant chemotherapy and radical nephroureterectomy for high risk upper tract urothelial carcinoma. Ghandour RA; Freifeld Y; Cheaib J; Singla N; Meng X; Kenigsberg A; Bagrodia A; Woldu S; Hoffman-Censits J; Enikeev D; Rapoport L; Petros FG; Raman JD; Pierorazio PM; Matin SF; Margulis V Urol Oncol; 2021 Nov; 39(11):788.e15-788.e21. PubMed ID: 34330655 [TBL] [Abstract][Full Text] [Related]
11. Trends in the use of neoadjuvant chemotherapy and oncological outcomes for high-risk upper tract urothelial carcinoma: a multicentre retrospective study. Hamaya T; Hatakeyama S; Tanaka T; Kubota Y; Togashi K; Hosogoe S; Fujita N; Kusaka A; Tokui N; Okamoto T; Yamamoto H; Yoneyama T; Yoneyama T; Hashimoto Y; Ohyama C BJU Int; 2021 Oct; 128(4):468-476. PubMed ID: 33484231 [TBL] [Abstract][Full Text] [Related]
12. Analysis of Neoadjuvant Chemotherapy Utilization, Pathologic Response, and Overall Survival in Upper Tract Urothelial Carcinoma. Xu VE; Adesanya O; Azari S; Islam S; Klein M; Drouaud A; Antar RM; Chang P; Smith A; Whalen MJ Clin Genitourin Cancer; 2024 Dec; 22(6):102224. PubMed ID: 39418788 [TBL] [Abstract][Full Text] [Related]
13. Longitudinal GFR trends after neoadjuvant chemotherapy prior to nephroureterectomy for upper tract urothelial carcinoma. Labbate CV; Hensley PJ; Miest TS; Qiao W; Adibi M; Shah AY; Chery L; Papadopoulos J; Siefker-Radtke AO; Gao J; Guo CC; Czerniak BA; Navai N; Kamat AM; Dinney CP; Campbell MT; Matin SF Urol Oncol; 2022 Oct; 40(10):454.e17-454.e23. PubMed ID: 35961847 [TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Chemotherapy in Elderly Patients With Upper Tract Urothelial Cancer: Oncologic Outcomes From a Multicenter Study. Grossmann NC; Pradere B; D'Andrea D; Schuettfort VM; Mori K; Rajwa P; Quhal F; Laukhtina E; Katayama S; Fankhauser CD; Xylinas E; Margulis V; Moschini M; Abufaraj M; Bandini M; Lonati C; Nyirady P; Karakiewicz PI; Fajkovic H; Shariat SF Clin Genitourin Cancer; 2022 Jun; 20(3):227-236. PubMed ID: 35125303 [TBL] [Abstract][Full Text] [Related]
15. Pre-therapy serum albumin-to-globulin ratio in patients treated with neoadjuvant chemotherapy and radical nephroureterectomy for upper tract urothelial carcinoma. Pradere B; D'Andrea D; Schuettfort VM; Foerster B; Quhal F; Mori K; Abufaraj M; Margulis V; Deuker M; Briganti A; Muilwijk T; Hendricksen K; Lotan Y; Karakiewic P; F Shariat S; World J Urol; 2021 Jul; 39(7):2567-2577. PubMed ID: 33067726 [TBL] [Abstract][Full Text] [Related]
16. Overview, Diagnosis, and Perioperative Systemic Therapy of Upper Tract Urothelial Carcinoma. Kolawa A; D'Souza A; Tulpule V Cancers (Basel); 2023 Sep; 15(19):. PubMed ID: 37835507 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of neoadjuvant and adjuvant chemotherapy for localized and locally advanced upper tract urothelial carcinoma: a systematic review and meta-analysis. Quhal F; Mori K; Sari Motlagh R; Laukhtina E; Pradere B; Rouprêt M; Necchi A; Moschini M; Shariat SF Int J Clin Oncol; 2020 Jun; 25(6):1037-1054. PubMed ID: 32206939 [TBL] [Abstract][Full Text] [Related]
18. Design and rationale of a single-arm phase II study of neoadjuvant Durvalumab and Gemcitabine associated with Cisplatin or Carboplatin for upper urinary tract urothelial cancer: the iNDUCT trial (NCT04617756). Calleris G; Rouprêt M; Seisen T; Bendjeddou L; Chevallier T; Masson-Lecomte A; Thibault C; Neuzillet Y; Audenet F; Xylinas E; Houédé N World J Urol; 2023 Dec; 41(12):3413-3420. PubMed ID: 37698632 [TBL] [Abstract][Full Text] [Related]
19. Survival Outcomes in Neoadjuvant Chemotherapy for High-grade Upper Tract Urothelial Carcinoma: A Nationally Representative Analysis. Khan AI; Taylor BL; Al Hussein Al Awamlh B; Posada Calderon L; Fainberg J; Elahjji R; Shoag J; Scherr DS Urology; 2020 Dec; 146():158-167. PubMed ID: 32896584 [TBL] [Abstract][Full Text] [Related]